Consumer litigation funding, a growing industry in the United States, is an alternative credit source for cash-strapped tort plaintiffs. Financiers give plaintiffs nonrecourse loans that are premised on lawsuit outcomes. This article is the first to empirically examine the effect of consumer litigation funding. Specifically, I explore the impact of nonrecourse loans on medical malpractice litigation outcomes by exploiting the variation in timing and geography from two Ohio policy changes: the Ohio Supreme Court’s 2003 ban of funding in Rancman v. Interim Settlement Funding Corporation and the state’s subsequent legislative legalization of funding in 2008. Using closed-claim data from the National Practitioner Data Bank, I find evidence that the availability of funding increases claim payment and claim duration.
